SIGA's Loss Narrows To $2.9 Million Even As Revenue Falls And Research Spending Drops
Nine-month profit fell to $6.1 million from $28.7 million as SIGA works toward a new U.S. government procurement contract.
SIGA Technologies, which sells the smallpox drug TPOXX to governments, narrowed its third-quarter loss to $2.9 million from $6.4 million a year earlier even as revenue fell to $1.3 million from $2.6 million. The results, released Monday in an SEC filing, came alongside a sharp drop in research spending.
Lower Spending, Smaller Loss
Research expenses totaled $2.6 million, compared with $7.1 million in the year-earlier quarter. SIGA's operating expenses overall fell to $7.8 million from $12.8 million, while its operating loss narrowed to $6.5 million from $10.2 million.
Product sales and related services brought in $0.2 million, down from $0.9 million. Research-and-development revenue accounted for $1.1 million, compared with $1.7 million a year earlier.
The quarterly loss per diluted share was $0.04, versus $0.09. A $2.6 million income-tax benefit, compared with $2.0 million a year earlier, reduced the bottom-line loss; before taxes, SIGA lost $5.5 million versus $8.4 million.
The first nine months tell a less favorable story. Revenue declined to $48.6 million from $90.8 million, including product sales and related services of $41.6 million versus $85.8 million. Net profit fell to $6.1 million, or $0.09 per diluted share, from $28.7 million, or $0.40.
The Final Stockpile Order
SIGA delivered approximately $26 million of intravenous TPOXX to the U.S. Strategic National Stockpile during the first nine months, completing the final procurement order under its existing contract. International customers received approximately $13 million of oral TPOXX, spread across two customers.
The company supplies oral TPOXX domestically and internationally, sometimes through distributors, and sells the intravenous version to the U.S. government. Government funding also supports development, manufacturing and post-approval work. SIGA uses third-party manufacturers to make and package its medicines.
Oral TPOXX received FDA approval in 2018; the intravenous version followed in 2022. SIGA has sold the drug to more than 30 countries.
Canada's Firm Purchases And Options
In October, the Canadian Department of National Defence awarded SIGA a contract covering up to approximately $15 million of oral TPOXX purchases by March 31, 2031. Approximately $9 million consists of firm commitments over the first three years; approximately $6 million depends on Canada exercising options.
Diem Nguyen, SIGA's chief executive officer, said the company is "actively pursuing opportunities with other international governments to further diversify our customer base over time."
Cash stood at $116.4 million on September 30, compared with $155.0 million at year-end 2025. SIGA paid a special cash dividend of $0.60 per share on April 23, 2026, following its declaration on March 26.
Dennis Hruby, executive vice president and chief scientific officer, retired Monday after more than 30 years with SIGA. He plans to remain an adviser.
SIGA says it continues working with the U.S. government toward a new TPOXX procurement contract.
Sources
- 8-K Filing — SIGA TECHNOLOGIES INC (SIGA) — SEC EDGAR
- Exhibit ef20085184_ex99-1.htm — SIGA TECHNOLOGIES INC 8-K exhibit — SEC EDGAR
- SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D. — Yahoo Finance
- SIGA Reports Financial Results for Three and Nine Months — globenewswire.com
- SIGA Announces Retirement of Chief Scientific Officer — globenewswire.com